Deleterious variants in BRCA1 or BRCA2, either germline or somatic, are most frequently observed in ovarian cancer (13.8%), castrate-resistant prostate cancer (11.8%), and breast cancer (6.8%), but can occur in many other cancer types as well [8,9]. This evidence concerns the gene BRCA2 and breast carcinoma.